Zynerba Pharmaceuticals Inc ZYNE:NASDAQ

Last Price$1.37Cboe Real-Time Last Sale as of 3:58PM ET 8/15/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.05(4.20%)
Bid (Size)$1.36 (196)
Ask (Size)$1.37 (100)
Day Low / High$1.29 - 1.37
Volume467.4 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/15/2022


Zynerba Pharmaceuticals Inc ( NASDAQ )

Price: $1.37
Change: +0.05 (4.20%)
Volume: 467.4 K
3:58PM ET 8/15/2022

Tonix Pharmaceuticals Holding Corp ( NASDAQ )

Price: $1.59
Change: +0.19 (13.21%)
Volume: 8.0 M
3:59PM ET 8/15/2022

Eyenovia Inc ( NASDAQ )

Price: $1.61
Change: -0.10 (5.85%)
Volume: 538.7 K
3:57PM ET 8/15/2022

Tyme Technologies Inc ( NASDAQ )

Price: $0.35
Change: +0.008 (2.28%)
Volume: 696.5 K
3:39PM ET 8/15/2022

Oncternal Therapeutics Inc ( NASDAQ )

Price: $1.22
Change: +0.06 (5.17%)
Volume: 642.0 K
3:59PM ET 8/15/2022

Read more news Recent News

-- Earnings Flash (ZYNE) ZYNERBA PHARMACEUTICALS Posts Q2 Loss $-0.24
7:00AM ET 8/10/2022 MT Newswires


Zynerba Pharmaceuticals to Raise Up to $20 Million in Share Sale Agreement With Lincoln Park Capital Fund
7:49AM ET 7/21/2022 MT Newswires

Zynerba Pharmaceuticals (ZYNE) said Thursday it entered into an agreement with Lincoln Park Capital Fund for the sale of up to $20 million of common...

Canaccord Genuity Adjusts Zynerba Pharmaceuticals' Price Target to $11 From $9, Reiterates Buy Rating
11:22AM ET 6/23/2022 MT Newswires

Zynerba Pharmaceuticals (ZYNE) has an average outperform rating and price target range of $1 to $11, according to analysts polled by Capital IQ. (MT...

Zynerba Pharmaceuticals Says Genetic Disorder Drug Improved Patient Symptoms in Phase 2 Trial
4:32AM ET 6/22/2022 MT Newswires

Zynerba Pharmaceuticals (ZYNE) said Tuesday its Zygel drug improved the behavioral symptoms of patients with a genetic disorder called chromosome 22q11.2...

View all Commentary and Analysis

Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow
1:58PM ET 8/14/2022 Seeking Alpha

Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow
1:09PM ET 3/16/2022 Seeking Alpha

Cannabis REITs: When They Go Low, We Get High
10:00AM ET 12/03/2021 Seeking Alpha

Revisiting Zynerba Pharmaceuticals
1:35PM ET 11/11/2021 Seeking Alpha

Company Profile

Business DescriptionZynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA. View company web site for more details
Address80 West Lancaster Avenue
Devon, Pennsylvania 19333
Number of Employees25
Recent SEC Filing08/10/202210-Q
Chairman & Chief Executive OfficerArmando Anido
PresidentTerri B. Sebree
Chief Financial Officer & VP-Corporate DevelopmentJames E. Fickenscher
Vice President-ClinicalNancy Tich

Company Highlights

Price Open$1.30
Previous Close$1.31
52 Week Range$0.84 - 4.65
Market Capitalization$62.5 M
Shares Outstanding45.8 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/21/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.93
Beta vs. S&P 500N/A
Revenue$86.0 K
Net Profit MarginN/A
Return on Equity-55.50%

Analyst Ratings as of 04/14/2022

Consensus RecommendationConsensus Icon
Powered by Factset